Glenn Lesser to Administration, Oral
This is a "connection" page, showing publications Glenn Lesser has written about Administration, Oral.
Connection Strength
0.292
-
Morrell RM, Tooze JA, Harmon MS, Carter AF, DeTroye AT, Lesser GJ. An automated system for detecting nonadherence in laboratory testing and monitoring for myelosuppression in patients receiving self-administered oral chemotherapy. J Oncol Pract. 2013 Sep; 9(5):e268-71.
Score: 0.111
-
Lesser GJ, Case D, Stark N, Williford S, Giguere J, Garino LA, Naughton MJ, Vitolins MZ, Lively MO, Shaw EG. A randomized, double-blind, placebo-controlled study of oral coenzyme Q10 to relieve self-reported treatment-related fatigue in newly diagnosed patients with breast cancer. J Support Oncol. 2013 Mar; 11(1):31-42.
Score: 0.109
-
Batchelor TT, Gerstner ER, Ye X, Desideri S, Duda DG, Peereboom D, Lesser GJ, Chowdhary S, Wen PY, Grossman S, Supko JG. Feasibility, phase I, and phase II studies of tandutinib, an oral platelet-derived growth factor receptor-ß tyrosine kinase inhibitor, in patients with recurrent glioblastoma. Neuro Oncol. 2017 04 01; 19(4):567-575.
Score: 0.036
-
Miller AA, Case D, Harmon M, Savage P, Lesser G, Hurd D, Melin SA. Phase I study of lenalidomide in solid tumors. J Thorac Oncol. 2007 May; 2(5):445-9.
Score: 0.018
-
Grossman SA, Carson KA, Batchelor TT, Lesser G, Mikkelsen T, Alavi JB, Phuphanich S, Hammour T, Fisher JD, Supko JG. The effect of enzyme-inducing antiseizure drugs on the pharmacokinetics and tolerability of procarbazine hydrochloride. Clin Cancer Res. 2006 Sep 01; 12(17):5174-81.
Score: 0.017